Aussie regulators give OK to Biogen's Fampyra for multiple sclerosis
This article was originally published in Scrip
Executive Summary
Biogen Idec won approval from the Australian Therapeutic Goods Administration for Fampyra (fampridine) modified release as a therapy to improve walking ability in adults with multiple sclerosis who have shown improvement after eight weeks of treatment.